UniProt Q8N5S9 · PDB · AlphaFold · Substrate: MBP + Ca-CaM · Clone: full-length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Ponatinib | 83.6% | 16.4% | 78.23 | 0.534 |
| 2 | Pacritinib | 70.3% | 29.7% | 88.64 | 0.452 |
| 3 | Ceritinib | 69.6% | 30.4% | 95.44 | 0.618 |
| 4 | Brigatinib | 64.5% | 35.5% | 82.96 | 0.513 |
| 5 | Midostaurin | 64.2% | 35.8% | 78.64 | 0.500 |
| 6 | Abemaciclib | 52.7% | 47.3% | 91.48 | 0.563 |
| 7 | Gilteritinib | 51.9% | 48.1% | 88.97 | 0.506 |
| 8 | Repotrectinib | 49.0% | 51.0% | 84.21 | 0.608 |
| 9 | Alectinib | 47.9% | 52.1% | 95.49 | 0.651 |
| 10 | Avapritinib | 42.2% | 57.8% | 97.73 | 0.644 |
| 11 | Entrectinib | 41.5% | 58.5% | 93.69 | 0.671 |
| 12 | Sunitinib | 40.2% | 59.8% | 91.73 | 0.524 |
| 13 | Lorlatinib | 38.5% | 61.5% | 97.24 | 0.694 |
| 14 | Quizartinib | 34.7% | 65.3% | 99.50 | 0.737 |
| 15 | Defactinib | 31.8% | 68.2% | 92.68 | 0.450 |
| 16 | Nintedanib | 25.0% | 75.0% | 90.23 | 0.608 |
| 17 | Crizotinib | 25.0% | 75.0% | 91.39 | 0.581 |
| 18 | Pazopanib | 24.3% | 75.7% | 97.49 | 0.672 |
| 19 | Pralsetinib | 21.9% | 78.1% | 93.43 | 0.643 |
| 20 | Tivozanib | 19.1% | 80.9% | 92.42 | 0.673 |
Paralog block
CAMKK1, CAMKK2
EMT expression
- Mesenchymal log2(TPM+1): 2.34
- Epithelial log2(TPM+1): 2.12
- Fold change: 0.21
- Status: No significant change
Selectivity landscape vs inhibition on CAMKK1
Each point is one of the 92 approved drugs; color = inhibition % on CAMKK1.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…